Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.70
-0.29 (-3.23%)
At close: Apr 28, 2026, 4:00 PM EDT
8.84
+0.14 (1.60%)
After-hours: Apr 28, 2026, 5:57 PM EDT
Kyverna Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Kyverna Therapeutics stock have an average target of 20.75, with a low estimate of 5.00 and a high estimate of 33. The average target predicts an increase of 138.51% from the current stock price of 8.70.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kyverna Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +129.89% | Apr 23, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $31 → $33 | Buy | Maintains | $31 → $33 | +279.31% | Dec 16, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $25 | Buy | Maintains | $20 → $25 | +187.36% | Dec 4, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $27 → $31 | Buy | Maintains | $27 → $31 | +256.32% | Oct 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $20 | Strong Buy | Maintains | $10 → $20 | +129.89% | Oct 27, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
16.48M
EPS This Year
-3.11
from -3.64
EPS Next Year
-3.04
from -3.11
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 39.9M | ||||||
| Avg | n/a | 16.5M | ||||||
| Low | n/a | 4.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.56 | -2.43 | ||||||
| Avg | -3.11 | -3.04 | ||||||
| Low | -3.63 | -3.68 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.